The breast cancer drug market in Russia is predicted to reach $226m by 2014, according to analysts.
Decision Resources say the market will be driven by a steady increase in the number of post-menopausal breast cancer cases.
Significant contributions will also come from a slight shift toward higher-cost chemotherapy regimens and increases in the use of targeted therapies thanks to new product launches in the non-hormonal segment of the market.
Decision Resources analyst Natalia Reoutova said that increasing competition from generics over the 2009–2014 period will not affect multinational companies’ share of non-hormonal agents due to the anticipated launch of new therapies.
“However, the impact will be greater in the hormonal breast cancer therapy market, where multinational companies’ sales share will decrease from 82% to 67% by 2014,” she said.
Decision Resources predicts Roche’s trastuzumab-DM1 and pertuzumab, Pfizer’s neratinib, Eisai’s eribulin and Abraxis’s Abraxane will command 23% of Russia’s breast cancer drug market.
